AMARYL TABLET

Страна: Канада

Език: английски

Източник: Health Canada

Активна съставка:

GLIMEPIRIDE

Предлага се от:

SANOFI-AVENTIS CANADA INC

АТС код:

A10BB12

INN (Международно Name):

GLIMEPIRIDE

дозиране:

4MG

Лекарствена форма:

TABLET

Композиция:

GLIMEPIRIDE 4MG

Начин на приложение:

ORAL

Броя в опаковка:

30

Вид предписание :

Prescription

Терапевтична област:

SULFONYLUREAS

Каталог на резюме:

Active ingredient group (AIG) number: 0146247003; AHFS:

Статус Оторизация:

CANCELLED POST MARKET

Дата Оторизация:

2018-06-07

Данни за продукта

_ _
_ _
_Page 1 of 49_
PRODUCT MONOGRAPH
Pr
AMARYL
®
glimepiride
Tablets 1, 2 and 4 mg
Manufacturer’s standard
Oral Hypoglycemic (Sulfonylurea)
sanofi-aventis Canada Inc.
2905 Place Louis R.-Renaud
Laval, Quebec H7V 0A3
Date of Revision:
December 29, 2016
Submission Control No.: 198596
s-a Version 5.0 dated December 23, 2016
_ _
_ _
_Page 2 of 49_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................... 3
SUMMARY PRODUCT INFORMATION
.................................................................... 3
INDICATIONS AND CLINICAL USE
..........................................................................
3
CONTRAINDICATIONS
...............................................................................................
4
WARNINGS AND PRECAUTIONS
..............................................................................
4
ADVERSE REACTIONS
................................................................................................
9
DRUG INTERACTIONS
..............................................................................................
12
DOSAGE AND ADMINISTRATION
..........................................................................
15
OVERDOSAGE
.............................................................................................................
17
ACTION AND CLINICAL PHARMACOLOGY
........................................................ 18
STORAGE AND STABILITY
......................................................................................
22
DOSAGE FORMS, COMPOSITION AND PACKAGING
......................................... 22
PART II: SCIENTIFIC INFORMATION
.................................................................................
23
PHARMACEUTICAL INFORMATION
......................................................................
23
CLINICAL TRIALS
......................................................................................................
24
DETAILED PHARMACOLOGY
...................................